



Case ID : 24010010650
 Patient Name : Mrs. E MALANI
 Age/DOB/Sex : 68 Years / / Female
 Hospital Name : Aegle Omics (Private) Limited, Colombo
 Physician Name : DR MAHAILAL WIJEKoon
 Regn Date : 17-Jul-2024 13:54
 Collection On : 15-Jul-2024 00:00
 Reported On : 20-Jul-2024 11:56
 Process AT : CORE-Gurugram
 Ref no :
 Sample Type : FFPE Block
 Report Status : Final

UNIQUE PATIENT ID: 112383

TEST NAME

HER2

SPECIMEN INFORMATION

Labelled as 558/24

CLINICAL HISTORY

Invasive breast carcinoma.

METHODOLOGY

Fluorescence In Situ Hybridization


DIAGNOSIS

FISH MARKER	Result
-------------	--------

HER2 (FISH)

Negative

Total number of cells scored	100
Total number of HER2 signals	185
Total number of CEP17 signals	172
Average HER2 signals/cells	1.85
Computed Ratio	1.08



Probe used: HEALTHCARE HER2/CEP17 dual color probe. HER2: Orange, CEP17: Green

CLINICAL INTERPRETATION

1. Negative for HER2/neu amplification as per ASCO 2018 guidelines.
2. Her2:CEP17 ratio is <2 and Average Her2 signals <4 (Group 5).



Case ID : 24010010650
Patient Name : Mrs. E MALANI
Age/DOB/Sex : 68 Years / / Female
Hospital Name : Aegle Omics (Private) Limited, Colombo
Physician Name : DR MAHAILAL WIJEKON
Regn Date : 17-Jul-2024 13:54
Collection On : 15-Jul-2024 00:00
Reported On : 20-Jul-2024 11:56
Process AT : CORE-Gurugram
Ref no :
Sample Type : FFPE Block
Report Status : Final

UNIQUE PATIENT ID: 112383

COMMENTS

1. Evaluation of this specimen shows a normal hybridization pattern. These findings are indicative that the patient is not eligible for anti HER2 therapy (Trastuzumab).
2. Her2 gene amplification is seen 18 to 20% of invasive breast cancers. These tumours show increased over all survival rate with Her2 targeted therapy such as Trastuzumab.
3. It has been recognised as a poor prognosis indicator in early breast cancer.
4. In cases where tumor heterogeneity is present, analysis of HER2 FISH on additional blocks is recommended for conclusive result.

REFERENCES

1. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists clinical Practice Guideline Focused Update
2. Antonio C. Wolff, M. Elizabeth Hale Hammond, Kimberly H. Allison, Brittany E. Harvey, Pamela B. Mangu, John M.S. Bartlett, Michael Bilous, Ian O. Ellis, Patrick Fitzgibbons, Wedad Hanna, Robert B. Jenkins, Michael F. Press, Patricia A. Spears, Gail H. Vance, Giuseppe Viale, Lisa M. McShane, and Mitchell Dowsett Journal of Clinical Oncology 2018 36:20, 2105-2122

Disclaimer:

- Testing only validated for FFPE specimens; specimens fixed in other than 10% neutral buffered formalin have not been validated using this method. Fixation time should not be less than 6 hours and not more than 72 hours for FISH testing.
- Specimens placed in decalcifying solution may have a false-negative result. This test is not FDA approved / cleared for specific uses.
- Repeat testing is recommended for discordant results.



Scan to Connect

If you have any questions about this report or would like to have a conversation about the test results, please feel free to reach out to us at

+91 88828 99999 or **info@corediagnostics.in**

CONDITIONS OF REPORTING

1. The tests are carried out in the lab with the presumption that the specimen belongs to the patient named or identified in the bill/test request form.
2. The test results relate specifically to the sample received in the lab and are presumed to have been generated and transported per specific instructions given by the physicians/laboratory.
3. The reported results are for information and are subject to confirmation and interpretation by the referring doctor.
4. Some tests are referred to other laboratories to provide a wider test menu to the customer.
5. CORE Diagnostics Pvt. Ltd. shall in no event be liable for accidental damage, loss, or destruction of specimen, which is not attributable to any direct and mala fide act or omission of CORE Diagnostics Pvt. Ltd. or its employees. Liability of CORE Diagnostics Pvt. Ltd. for deficiency of services, or other errors and omissions shall be limited to fee paid by the patient for the relevant laboratory services.

This report is the property of CORE Diagnostics. The information contained in this report is strictly confidential and is only for the use of those authorized. If you have received this report by mistake, please contact CORE Diagnostics

CORE Diagnostics (Central Reference Lab) - Gurugram

406, Udyog Vihar, Phase III, Gurugram, Haryana - 122016

CORE Diagnostics Satellite Lab - New Delhi

C-13, 1st Floor, Green Park Extension, New Delhi - 110016

67, Hargobind Enclave, New Delhi - 110092

H64, Block H, Bali Nagar, New Delhi - 110015

CORE Diagnostics Satellite Lab - Bhubaneswar

Plot No. - 249, Near Police Academy, AIIMS Nagar,
Patrapada, Bhubaneswar - 751019

CORE Diagnostics Satellite Lab - Bangalore

1st Floor, KMK Tower, 142 KH Road,
Bangalore - 560027

CORE Diagnostics Satellite Lab - Lucknow

J.S. Tower, Plot No. - K-702, Sector K, Ashiyana, Near Raj
Luxmi Sweets, Lucknow, Uttar Pradesh - 226012

CORE Diagnostics Satellite Lab - Guwahati

Ground Floor, Honuram Boro Path, Shubham Velocity, GS Road,
Dispur, Kamrup Metropolitan, Guwahati, Assam - 781005

CORE Diagnostics Satellite Lab -Hyderabad

S. No.155, Mahalakshmi Trade Center, 2nd Floor, Thokatta -Village,
Diamond Point Road, Bowenpally, Secunderabad,Telangana-500009